

---

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**SCHEDULE 13D**

Under the Securities Exchange Act of 1934

**(Amendment No. 7)\***

**Tango Therapeutics, Inc.**

---

**(Name of Issuer)**

**Common Stock, \$0.001 par value per share**

---

**(Title of Class of Securities)**

**87583X109**

---

**(CUSIP Number)**

**Josh La Grange**  
**Fried, Frank, Harris, Shriver & Jacobson, 801 17th Street, NW**  
**Washington, DC, 20006**  
**202-639-7497**

---

**(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)**

**12/30/2024**

---

**(Date of Event Which Requires Filing of This Statement)**

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

**SCHEDULE 13D**

**CUSIP No. 87583X109**

Name of reporting person

1

BCTG Holdings, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

3 SEC use only

4 Source of funds (See Instructions)

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Number of  
Shares

Shared Voting Power

Beneficially 8

Owned by

0.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

0.00

Aggregate amount beneficially owned by each reporting person

11

0.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0 %

Type of Reporting Person (See Instructions)

14

OO

## SCHEDULE 13D

**CUSIP No.** 87583X109

Name of reporting person

1

MVA Investors, LLC

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3 SEC use only

Source of funds (See Instructions)

4

OO

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

DELAWARE

Number of  
Shares

7 Sole Voting Power

Beneficially	0.00
Owned by	Shared Voting Power
Each	8
Reporting	326,886.00
Person	Sole Dispositive Power
With:	9
	0.00
	Shared Dispositive Power
	10
	326,886.00
	Aggregate amount beneficially owned by each reporting person
11	326,886.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	<input type="checkbox"/>
	Percent of class represented by amount in Row (11)
13	0.3 %
	Type of Reporting Person (See Instructions)
14	OO

## SCHEDULE 13D

**CUSIP No.** 87583X109

1	Name of reporting person
	Davis Aaron I.
	Check the appropriate box if a member of a Group (See Instructions)
2	<input type="checkbox"/> (a)
	<input checked="" type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions)
	OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	<input type="checkbox"/>
6	Citizenship or place of organization
	UNITED STATES
	Sole Voting Power
7	32,500.00
Number of	Shared Voting Power
Shares	8
Beneficially	10,707,885.00
Owned by	Sole Dispositive Power
Each	9
Reporting	32,500.00
Person	Shared Dispositive Power
With:	10
	10,707,885.00
	Aggregate amount beneficially owned by each reporting person
11	10,740,385.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)  
 10 %  
 Type of Reporting Person (See Instructions)

14 IN

**SCHEDULE 13D**

**CUSIP No.** 87583X109

1 Name of reporting person  
 Boxer Capital Management, LLC  
 Check the appropriate box if a member of a Group (See Instructions)

2  (a)  
 (b)

3 SEC use only  
 Source of funds (See Instructions)

4 OO  
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5   
 Citizenship or place of organization

6 DELAWARE  
 Sole Voting Power

7 0.00  
 Number of Shares Beneficially Owned by Each Reporting Person With:  
 Shared Voting Power

8 10,380,999.00  
 Sole Dispositive Power

9 0.00  
 Shared Dispositive Power

10 10,380,999.00  
 Aggregate amount beneficially owned by each reporting person

11 10,380,999.00  
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

13 Percent of class represented by amount in Row (11)  
 9.7 %  
 Type of Reporting Person (See Instructions)

14 IA, OO

# SCHEDULE 13D

## Item 1. Security and Issuer

Title of Class of Securities:

(a) Common Stock, \$0.001 par value per share

Name of Issuer:

(b) Tango Therapeutics, Inc.

Address of Issuer's Principal Executive Offices:

(c) 201 BROOKLINE AVENUE, SUITE 901, BOSTON, MASSACHUSETTS , 02215.

**Item 1 Comment:** With respect to Boxer Capital Management, LLC ("BCM"), BCTG Holdings, LLC ("BCTG Holdings"), MVA Investors, LLC ("MVA Investors") and Aaron I. Davis (together with BCM, BCTG Holdings and MVA Investors, the "Reporting Persons"), this amendment (this "Amendment No. 7") further amends and supplements the statement on Schedule 13D filed on August 20, 2021 (the "Original Filing") by BCTG Holdings, MVA Investors, Mr. Davis and certain other persons with respect to the Common Stock, par value \$0.001 (the "Common Stock") of Tango Therapeutics, Inc. (the "Issuer"), as previously amended and filed on January 4, 2022 ("Amendment No. 1"), August 16, 2023 ("Amendment No. 2"), October 18, 2023 ("Amendment No. 3"), October 15, 2024 ("Amendment No. 4"), October 28, 2024 (Amendment No. 5), and November 7, 2024 ("Amendment No. 6"). Capitalized terms used herein but not defined herein shall have the respective meanings defined in the Original Filing, as previously amended. The Original Filing, as previously amended, is further amended hereby only as specifically set forth herein, provided that with respect to any Item amended herein, if such Item is incorporated by reference into any other Item in the Original Filing, as previously amended, such incorporation by reference is also amended hereby. BCTG Holdings reports herein that it has ceased to beneficially own more than 5% of the outstanding shares of Common Stock.

## Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended by the addition of the following: On December 30, 2024, BCTG Holdings distributed 6,770,357 shares of Common Stock to an account managed by BCM and 218,093 shares of Common Stock to MVA Investors, for no consideration. Consequently, BCTG Holdings has ceased to beneficially own any shares of Common Stock of the Issuer.

## Item 4. Purpose of Transaction

Item 4 is hereby amended by the addition of the following: The disclosure set forth above in Item 3 is hereby incorporated herein.

## Item 5. Interest in Securities of the Issuer

For information regarding beneficial ownership, see the information presented on the cover pages. All percentages are based on 107,450,318 shares of the Issuer's Common Stock outstanding, which is (i) 107,417,818 shares of the Issuer's Common Stock outstanding as of November 1, 2024 as set forth in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2024, plus (ii) 32,500 shares of Common Stock subject to options to purchase shares of Common Stock, held by Mr. Davis, exercisable in the next 60 days. The Reporting Persons may be deemed to beneficially own, in the aggregate, 10,740,385 shares of Common Stock, representing beneficial ownership of 9.996% of the outstanding shares of Common Stock.

(a) For information regarding beneficial ownership, see the information presented on the cover pages. All percentages are based on 107,450,318 shares of the Issuer's Common Stock outstanding, which is (i) 107,417,818 shares of the Issuer's Common Stock outstanding as of November 1, 2024 as set forth in the Issuer's 10-Q filed with the Securities and Exchange Commission on November 6, 2024, plus (ii) 32,500 shares of Common Stock subject to options to purchase shares of Common Stock, held by Mr. Davis, exercisable in the next 60 days. The Reporting Persons may be deemed to beneficially own, in the aggregate, 10,740,385 shares of Common Stock, representing beneficial ownership of 9.996% of the outstanding shares of Common Stock.

(b) Other than as described herein in Item 4 or transactions previously reported on Form 4, the Reporting Persons have not engaged in any transactions in the Common Stock since Amendment No.6.

(c) Other than as described herein and except as may result from indirect interests of investors in MVA Investors or BCM, no persons other than the Reporting Persons have the right to receive or the power to direct the receipt of dividends, or proceeds of sale of such securities outlined in this report.

(d) As described in Item 3 above, as of December 30, 2024, BCTG Holdings ceased to beneficially own more than 5% of the outstanding shares of Common Stock.

(e)

## SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BCTG Holdings, LLC

Signature: /s/ Aaron I. Davis

Name/Title: Aaron I. Davis, Manager

Date: 01/02/2025

MVA Investors, LLC

Signature: /s/ Aaron I. Davis

Name/Title: Aaron I. Davis, Authorized Signatory

Date: 01/02/2025

Davis Aaron I.

Signature: /s/ Aaron I. Davis

Name/Title: Aaron I. Davis, Individually

Date: 01/02/2025

Boxer Capital Management, LLC

Signature: /s/ Aaron I. Davis

Name/Title: Aaron I. Davis, Managing Member

Date: 01/02/2025